Summary
Two hundred eight patients were studied in a prospective, controlled, double-blind multicenter trial comparing auranofin (AUR), gold sodium thiomalate (GST), and placebo. One hundred sixty-one patients completed at least 20 weeks of therapy. Response to a variety of measures of efficacy was generally modest for both gold treatment groups although improvement was continuing in both groups at the end of the study. There was statistically significant improvement with both gold preparations compared to placebo for the number of tender joints, the joint tenderness score, and physician assessment of disease severity. GST was also significantly better than placebo for the joint swelling score. GST demonstrated more improvement in patients with anemia and thrombocytosis compared to the other treatment groups and both gold preparations were superior to placebo in improvement of an elevated erythrocyte sedimentation rate. Twenty-seven percent of patients on GST were withdrawn from the study for adverse drug reaction with rash and stomatitis being the predominant cause. Only 6% of patients on AUR were withdrawn for untoward drug effect. The time of onset of the adverse reactions is discussed. The two gold preparations were similar in efficacy although AUR was better tolerated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Research Subcommittee of the Empire Rheumatism Council. Gold Therapy in Rheumatoid Arthritis: Report of a multi-centre controlled trial. Ann Rheum Dis 1960, 19, 95–117.
The Cooperating Clinics Committee of the American Rheumatism Association.A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973, 16, 353–358.
Sigler, J.W., Bluhm, G.B., Duncan, H., Sharp, J.T., Ensign, D.C., McCrum, W.R. Gold salts in the treatment of rheumatoid arthritis: A double-blind study. Ann Intern Med, 1974, 80, 21–26.
Schattenkirchner, M., Kaik, B., Muller-Fassbend-er, H., Rau, R., Zeidler, H. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study. J Rheumatol 1982, (Suppl 8), 9, 184–189.
Katz, W.A., Alexander, S., Bland, J.H., Blechman, W., Bluhm, G.B., Bonebrake, R.A., Falbo, A., Greenwald, R.A., Hartman, S., Hobbs, T., Indenbaum, S., Lergier, J.E., Lanier, B.G., Lightfoot, R.W. Jr., Phelps, P., Sheon, R.P., Torretti, D., Wenger, M.E., Wilske, K. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol 1982, (Suppl 8), 9, 173–178.
Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C., Boyce, E., Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1983, 26, 1303–1315.
Ropes, M.W., Bennett, G.A., Cobb, S., Jacox, R., Jessar, R.A. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958, 9, 175–176.
The Cooperating Clinics Committee of the American Rheumatism Association: A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965, 8, 302–334.
Steinbrocker, O., Treager, C.H., Batterman, R.C. Therapeutic criteria in rheumatoid arthritis. J Amer Med Assoc 1949, 140, 659–662.
Hutchinson, R.M., Davis, P., Jayson, M.I.V. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis 1976, 35, 138–142.
Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C., Boyce, E., Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: Subsets of responders. J Rheumatol 1983, in press.
Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C, Boyce, E., Samuelson, CO., Altz-Smith, M., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: Response by treatment duration. Excerpta Medica 1983, 7, 115–132.
Williams, H.J., Ward, J.R., Egger, M.J., Reading, J.C, Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis. Scand J Rheumatol 1983, in press.
Srinivasan, R., Miller, B.L., Paulus, H.E. Longterm chrysotherapy in rheumatoid arthritis. Arthritis Rheum 1979, 22, 105–110.
Flower, R.J., Moncada, S., Vane, J.R. Analgesic-antipyretics and anti-inflammatory agents; Drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics, 6th Edition. Editors: Gilman, A.G., Goodman, L.S., Gilman, A. New York, Macmillan Publishing Company, 1980, 715–716.
Menard, H.A., Beaudet, F., Davis, P., Harth, M., Percy, J.S., Russell, A.S., Thomson, J.M. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol 1982; (Suppl 8) 9, 179–183.
Bandilla, K., Gross, D., Gross, W., Herrlinger, J-D., Kriegel, W., Muller, W., Siegmeth, W., Tausch, G., Thumb, N., Wagenhauser, F.K. Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthritis. J Rheumatol 1982, (Suppl 8), 9, 154–159.
Kean, W.F., Anastassiades, T.P. Long term chrysotherapy. Incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979, 22, 495–501.
Penneys, N.S., Ackerman, A.B., Gottlieb, N.L. Gold dermatitis. A clinical and histopathological study. Arch Dermatol 1974, 109, 372–376.
Stein, H.B., Urowitz, M.B. Gold induced enterocolitis: Case report and literature review. J Rheumatol 1976, 3, 21–26.
Berglof, F-E., Berglof, K., Walz, D.T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol 1978, 5, 68–74.
Davis, P., Hughes, G.R.V. Significance of eosinophilia during gold therapy. Arthritis Rheum 1974, 17, 964–968.
Gottlieb, N.L. Chrysotherapy. Bull Rheum Dis 1976-1977, 27, 912–917.
Coblyn, J.S., Weinblatt, M., Holdsworth, D., Glass, D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981, 95, 178–181.
Smith, P.R., Brown, G.M.M., Meyers, O.L. An open comparative study of auranofin vs gold sodium thiomalate. J Rheumatol 1982, (suppl 8) 9, 190–196.
Silverberg, D.S., Kidd, E.G., Shnitka, T.K., Ulan, R.A. Gold nephropathy. A clinical and pathologic study. Arthritis Rheum 1970, 13, 812–825.
Favreau, M., Tannenbaum, H., Lough, J. Hepatic toxicity associated with gold therapy. Ann Intern Med 1977, 87, 717–719.
Halla, J.T., Hardin, J.G., Linn, J.E. Postinjection nonvasomotor reactions during chrysotherapy. Constitutional and rheumatic symptoms following injections of gold salts. Arthritis Rheum 1977, 20, 1188–1191.
Winterbauer, R.H., Wilske, K.R., Wheelis, R.F. Diffuse pulmonary injury associated with gold treatment. N Engl J Med 1976, 294, 919–921.
Gould, P.W., McCormack, P.L., Palmer, D.G. Pulmonary damage associated with sodium aurothiomalate therapy. J Rheumatol 1977, 4, 252–260.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, H.J., Ward, J.R., Egger, M.J. et al. Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis Cooperative systematic studies of rheumatic diseases. Clin Rheumatol 3 (Suppl 1), 39–50 (1984). https://doi.org/10.1007/BF03342621
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03342621